Typesetting │ Shuicheng WenIn June 2022, the FDA approvedNovo NordiskDeveloped by the companySemaglutide（Semaglutide）As a weight-loss drug on the market, the medication quickly gained global popularity in the same year, achieving sales exceeding 10 billion US dollars. This is a peptide-based GLP-1 receptor.（GLP-1R）Agonist, in previous clinical trials, semaglutide achieved a 15% weight loss effect in obese patients.(Once weekly injection, 2.4mg each time, for 68 weeks).AndEli LillyGIP/GLP-1 Receptor Dual Agonist Developed by the CompanyTirzepatide（Tirzepatide）Achieved the strongest drug weight loss effect to date. 2023On October 15, Eli Lilly and Company, in collaboration with a research team from the University of Pennsylvania and other institutions, published in a top international medical journal.Nature MedicinePublish Papers【1】。This project is namedResults from the Phase 3 clinical trial of SURMOUNT-3 show, over a 12-week periodStrengthen Lifestyle Interventions(Including low-calorie diet, exercise, and frequent counseling)After useTirzepatide（Tizepatide）Over a treatment period of 72 weeks, totaling 84 weeks,Participants who are obese or overweight but do not have diabetesThe average weight loss was26.6%(29.2 kg). This data刷新了directly usingTirzepatide（Tizepatide）Weight Loss Effect Record at 72 Weeks of Treatment.October 26, 2023BioAge LabsAnnounced the acquisition ofEli Lillywith the support, toMuscle Regeneration TherapyWith Eli LillyTirzepatide（Tirzepatide）Combined, for aClinical Trials for Healthier Weight Loss。The financial details of this cooperation have not been disclosed.BioAge Retains Exclusive Worldwide Rights to Develop and Commercialize Azelaprag for All Indications.It is reported that BioAge will conduct research on its oral Apelin receptor agonistAzelapra（BGE-105）With Eli Lilly and CompanyGIP/GLP-1 Receptor Dual Agonist TIrzepatide combination undergoes Phase 2 clinical trial, expected to officially commence by mid-2024. The primary goal is weight loss, with secondary objectives focusing on other potential benefits. Additionally, BioAge will collect information on aging-related biomarkers from participants.AzelapraYesAgonist of Apelin receptor, mimickingApelin Activity.Apelin is a "myokine" peptide released after exercise. Apelin acts on skeletal muscle, heart, and the central nervous system, regulating metabolism and promoting muscle regeneration.。Research by BioAge shows,In a person's lifetime, overallApelin levels will gradually decrease, andPeople with higher Apelin levelsWith stronger physical functions and longer lifespan.BioAge has previously combined Azelaprag with Tirzepatide in preclinical mouse models, showing advantages compared to using either drug alone.TirzepatideBetter weight loss results.BioAge stated that the combination of Azelaprag and Tirzepatide,Benefits in energy metabolism, increased insulin sensitivity, and reduced fat mass.In December 2022, BioAge announcedAzelapragResults from the Phase 1b clinical trial in humans showed,Azelaprag can prevent muscle atrophy in healthy elderly individuals aged 65 or older and maintain muscle protein synthesis.LikeSemaglutide（Semaglutide）AndTirzepatide（Tirzepatide）This is mainly based onGLP-1The drugs have a significant weight loss effect, but their core principle of weight reduction is to lower the user's appetite and calorie intake. Therefore,These drugs bring about weight loss whileWill also lead to a decline in muscle mass.。In this collaboration, Eli Lilly and Company will not only provide Tirzepatide but also offer its clinical development team to help advance this new clinical study.CEO of BioAgeKristen FortneyDr. said,This Phase 2 clinical trial is designed to evaluateWhether Azelaprag can significantly increase incretin（GLP-1、GIP）The weight loss effects of such drugs. This combination can enhance the performance of injectable and orally administered incretin drugs. The oral administration route of Azelaprag makes it an exciting combination partner for the next generation of oral incretin drugs currently under development. Additionally, Azelaprag offers extra benefits that may help with...Promote Healthier Weight Loss. Treating obesity could potentially prevent or delay multiple age-related diseases and significantly increase the lifespan of a large portion of the population.BioAge LabsIs an anti-aging research company,Dedicated to developing treatments for diseases and extending healthy lifespan by mapping the human aging atlas.. The company has currently accumulated financing$127 million。BioAgeThere are currently 3 research directions, respectively used for treatmentMetabolism and Muscle Aging、ImmunosenescenceAndBrain Aging。https://www.nature.com/articles/s41591-023-02597-whttps://www.businesswire.com/news/home/20231026896677/en/
SettingsStar Mark, so as not to miss exciting tweetsWelcome to share on Moments and WeChat groupsTo promote the dissemination and exchange of cutting-edge research, we have established severalProfessional Exchange Group, Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include a note when adding WeChat:School/Professional/Name, if it isPI/Professor, please also indicate.
PointIn View, Convey Your Taste
